TP53 and pancreatic ductal adenocarcinoma: Furthermore, in a recent study (Patra et al., 2018), malignant transformation (pancreatic ductal adenocarcinomas, PDAs) of a benign pancreatic disorder, intraductal papillary mucinous neoplasm (IPMN), induced by GNAS mutation, with the addition of TP53 loss was reported, supporting the significant role of TP53 in the progression of benign disease with pre‐existing GNAS mutation to a malignant state.